◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.